Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response…

By C. R. Rocha Lima, M. Green, R. Rotche, W. Miller, G. Jeffrey, L. Cisar, A. Morganti, N. Orlando, G. Gruia, L. Miller. Journal of Clinical Oncology, 2004

619 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Surgery

View Paper: https://www.semanticscholar.org/paper/dd3b7554a65203091ad88b8f57d7c8a5edb6946f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. D. Schrag
2. D. Niedzwiecki
3. H. Kindler
4. F. Innocenti
5. H. Hurwitz
6. R. Goldberg
7. D. Hollis
8. S. Sutherland

Citations in the corpus

• Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). (2010, background): “Negative phase III results despite promising single-arm phase II data are, unfortunately, a common outcome in pancreatic cancer trials.(3-10) These collective data suggest that in this disease, a single-arm, phase II trial design may not be not optimal.”